论文部分内容阅读
目的探讨重组人白细胞介素-11(rhIL-11)治疗化疗后血小板减少症的疗效和用药方法。方法回顾性分析该科2000年2月至2004年9月共38例化疗后出现Ⅲ～Ⅳ度血小板减少患者的治疗效果。对照组18例,用利血生、升血小板胶囊等药物;治疗组20例,用rhIL-11。结果治疗组Plt<50×109/L持续时间(2.5d)明显少于对照组(5.1d),差异有显著性(P<0.01);治疗组血小板恢复正常,既Plt>100×109/L所需时间(5.9d)明显少于对照组(13.5d),差异有显著性(P<0.01);停药后血小板数量并未明显回落,能稳定在正常水平。结论重组人白细胞介素-11(rhIL-11)是一种有效、安全的治疗化疗后血小板减少的药物。
Objective To investigate the therapeutic effect of rhIL-11 on thrombocytopenia after chemotherapy and the treatment of rhIL-11. Methods A retrospective analysis of the department from February 2000 to September 2004 a total of 38 patients after Ⅲ ~ Ⅳ thrombocytopenia treatment effect. The control group of 18 cases, with reserpine, ascending platelet capsules and other drugs; treatment group of 20 patients with rhIL-11. Results Compared with control group (P <0.01), Plt <50 × 109 / L for 2.5d in treatment group was significantly less than that in control group (P <0.01). Platelets in treatment group returned to normal with Plt> 100 × 109 / L The required time (5.9d) was significantly less than the control group (13.5d), the difference was significant (P <0.01); after stopping the platelet number did not significantly decline, stable at normal levels. Conclusion Recombinant human interleukin-11 (rhIL-11) is an effective and safe drug for the treatment of thrombocytopenia after chemotherapy.